FibroGen Inc. (NASDAQ:FGEN) insider K Peony Yu sold 2,345 shares of the firm’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $18.66, for a total transaction of $43,757.70. Following the sale, the insider now owns 206,502 shares in the company, valued at approximately $3,853,327.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of FibroGen Inc. (NASDAQ:FGEN) opened at 21.30 on Tuesday. FibroGen Inc. has a 52-week low of $14.38 and a 52-week high of $31.90. The firm’s market cap is $1.34 billion. The company’s 50-day moving average is $18.84 and its 200 day moving average is $18.41.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by $0.01. FibroGen had a negative net margin of 61.90% and a negative return on equity of 48.66%. On average, analysts expect that FibroGen Inc. will post ($1.25) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of FibroGen by 5.0% in the second quarter. BlackRock Fund Advisors now owns 2,053,134 shares of the biopharmaceutical company’s stock valued at $33,692,000 after buying an additional 96,844 shares during the last quarter. State Street Corp boosted its position in shares of FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 174,369 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of FibroGen by 5.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,286,883 shares of the biopharmaceutical company’s stock valued at $21,118,000 after buying an additional 69,815 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of FibroGen by 0.3% in the second quarter. JPMorgan Chase & Co. now owns 1,282,804 shares of the biopharmaceutical company’s stock valued at $21,051,000 after buying an additional 3,482 shares during the last quarter. Institutional investors and hedge funds own 49.82% of the company’s stock.

Separately, Credit Suisse Group AG restated a “buy” rating and set a $37.00 price target on shares of FibroGen in a research report on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $33.25.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.